Giuseppe Neola retweetledi
Insights on PARPi in adv HGSOC: efficacy independent of BRCA domain defects or mutation types. Numerically longer mPFS in pts with DBD defects. Check our new study in @FrontOncology! #OvarianCancer #PARPinhibitors Thanks to @CarmineDeA1 and all co-authors. frontiersin.org/journals/oncol…
English